<bill session="117" type="s" number="670" updated="2023-03-08T20:12:35Z">
  <state datetime="2021-03-10">REFERRED</state>
  <status>
    <introduced datetime="2021-03-10"/>
  </status>
  <introduced datetime="2021-03-10"/>
  <titles>
    <title type="display">Speeding Therapy Access Today Act of 2021</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act to accelerate development of therapies across the spectrum of rare diseases and conditions and facilitate patient access to such therapies, and for other purposes.</title>
    <title type="short" as="introduced">Speeding Therapy Access Today Act of 2021</title>
  </titles>
  <sponsor bioguide_id="K000367"/>
  <cosponsors>
    <cosponsor bioguide_id="W000437" joined="2021-03-10"/>
  </cosponsors>
  <actions>
    <action datetime="2021-03-10">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-03-10" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="1730" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Advisory bodies"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Executive agency funding and structure"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Manufacturing"/>
    <term name="Medical research"/>
    <term name="Research administration and funding"/>
  </subjects>
  <amendments/>
  <summary date="2021-06-23T23:35:46Z" status="Introduced in Senate">Speeding Therapy Access Today Act of 2021

This bill requires and authorizes various actions to accelerate the development of therapies for rare diseases.

The Food and Drug Administration (FDA) shall establish the Intercenter Institute on Rare Diseases and Conditions. The institute shall (1) coordinate engagement with relevant stakeholders, (2) build the FDA's expertise in the review of medical products to treat rare diseases, (3) coordinate regulatory science initiatives related to rare diseases, (4) establish and implement a program to make recommendations to address challenges associated with developing medical products to treat rare diseases in an individual or in very small populations, (5) convene a stakeholder meeting to consider potential amendments to labels for medical products to treat rare diseases, and (6) establish and carry out a program to facilitate voluntary communication between the sponsors of such medical products and third-party payers (e.g., insurance companies).

The bill also authorizes the FDA to make grants to assist in developing practices related to the development and production of individualized therapies or therapies to treat very small populations.

The bill also establishes an advisory committee to advise the FDA on issues related to the development of therapies to treat rare diseases.</summary>
</bill>
